- General Drug Summary
- Drug Name
- Dehydroepiandrosterone
- Description
- In Canada, a prescription is required to buy DHEA.
- Also Known As
- 3-beta-Hydroxy-5-androsten-17-one; 5-Dehydroepiandrosterone; 5-DHEA; DHA; DHEA; Prasterone
- Categories
- Adjuvants, Immunolog
- Structure
- Summary In Neonatal Jaundice
-
1 record(s) for Dehydroepiandrosterone Adverse Event in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 24104695
- Dehydroepiandrosterone
- Adverse Event
- Clinical Trial
- Summary
- Lower concentration of DHA (10 mg/kg), total bilirubin significantly increased in neonatal hUGT1 mice, which are human Neonatal jaundice models.
- Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia. Scientific reports, 2013 [Go to PubMed]
- While breast milk has been known as a cause of neonatal hyperbilirubinemia, the underlying mechanism of breast milk-induced jaundice has not been clarified. Here, the impact of fatty acids on human UDP-glucuronosyltransferase (UGT) 1A1--the sole enzyme that can metabolize bilirubin--were examined. Oleic acid, linoleic acid, and docosahexaenoic acid (DHA) strongly inhibited UGT1A1 activity. Forty-eight hours after a treatment with a lower concentration of DHA (10 mg/kg), total bilirubin significantly increased in neonatal hUGT1 mice, which are human neonatal jaundice models. In contrast, treatments with higher concentrations of fatty acids (0.1-10 g/kg) resulted in a decrease in serum bilirubin in hUGT1 mice. It was further demonstrated that the treatment with higher concentrations of fatty acids induced UGT1A1, possibly by activation of peroxisome proliferator-activated receptors. Our data indicates that activation of peroxisome proliferator-activated receptors would increase UGT1A1 expression, resulting in eduction of serum bilirubin levels in human infants.